Prevention or treatment of ARDS with aspirin: A review of preclinical models and meta-analysis of clinical studies

Shock

Volumn 47, Issue 1, 2017, Pages 13-21

  Panka, Bernardo Amisa ^a,b   De Grooth, Harm Jan ^a,c   Spoelstra De Man, Angelique Maria Elisabeth ^a,c   Looney, Mark ^d   Tuinman, Pieter Roel ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b S' Lands Hospitaal Paramaribo ^*  (Suriname)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; ARDS; Aspirin; Intensive Care; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; BH3 PROTEIN; CASPASE 3; CCAAT ENHANCER BINDING PROTEIN BETA; COMPLEMENT COMPONENT C5; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLUTATHIONE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEUKOTRIENE A4; MALONALDEHYDE; NITRIC OXIDE; PROSTAGLANDIN; TUMOR NECROSIS FACTOR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; CELL INTERACTION; COHORT ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; EXTRACELLULAR TRAP; HEMODYNAMICS; HUMAN; LIPID PEROXIDATION; LUNG ALVEOLUS MACROPHAGE; LUNG EDEMA; LUNG MECHANICS; META ANALYSIS; NEUTROPHIL; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PNEUMONIA; PRECLINICAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE; ANIMAL; DRUG EFFECTS; METABOLISM; THROMBOCYTE ACTIVATION;

ANIMALS; ASPIRIN; HUMANS; PLATELET ACTIVATION; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84988584610     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000745     Document Type: Review

References (69)

1. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 342(18):1334-1349, 2000.
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med 353(16):1685-1693, 2005.
3. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand J-A, Villar J, Thorsteinsson A, et al.: Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 30(1):51-61, 2004.
4. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, et al.: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315(8):788-800, 2016.
5. Murray JF, the staff of the Division of Lung Diseases, National Heart, Lung and Blood Institute. Mechanisms of acute respiratory failure. Am Rev Respir Dis 115(6):1071-1078, 1977.
6. Eltzschig HK, Carmeliet P: Hypoxia and inflammation. N Engl J Med 364(20):1976-1977, 2011.
7. Saldeen T: Trends in microvascular research. The microembolism syndrome. Microvasc Res 11(2):227-259, 1976.
8. Greene R, Zapol WM, Snider MT, Reid L, Snow R, O'Connell RS, Novelline RA: Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis 124(5):593-601, 1981.
9. Zarbock A, Ley K: The role of platelets in acute lung injury (ALI). Front Biosci (Landmark Ed) 14:150-158, 2009.
10. Zarbock A, Polanowska-Grabowska RK, Ley K: Platelet-neutrophil-inter-actions: linking hemostasis and inflammation. Blood Rev 21(2):99-111, 2007.
11. Maderna P, Godson C: Lipoxins: resolutionary road. Br J Pharmacol 158(4):947-959, 2009.
12. Yadav HKD: Platelets in the pathogenesis of acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 309(9):915-923, 2015.
13. Yaguchi A, Lobo FLM, Vincent J-L, Pradier O: Platelet function in sepsis. J Thromb Haemost 2(12):2096-2102, 2004.
14. Katz JN, Kolappa KP, Becker RC: Beyond thrombosis: the versatile platelet in critical illness. Chest 139(3):658-668, 2011.
15. Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, Lösche W: Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 17(4):263-268, 2002.
16. Hinshaw LB, Solomon LA, Erdös EG, Reins DA, Gunter BJ: Effects of acetylsalicylic acid on the canine response to endotoxin. J Pharmacol Exp Ther 157(3):665-671, 1967.
17. Halushka PV, Wise WC, Cook JA: Protective effects of aspirin in endotoxic shock. J Pharmacol Exp Ther 218(2):464-469, 1981.
18. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW: SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol 14(1):43, 2014.
19. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. [cited Sep 1, 2015] Available at: http://www.ohri.ca/Programs/clinical-epidemiology/nosgen.pdf. Accessed May 14, 2015.
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17(1):1-12, 1996.
21. OCEBM Levels of Evidence Working Group: The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. Available at: http://www.cebm.net/index.aspx?o=5653. Accessed July 19, 2016.
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560, 2003.
23. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101, 1994.
24. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634, 1997.
25. Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1-48, 2010.
26. Leeman M, Lejeune P, Hallemans R, Melot C, Naeije R: Effects of increased pulmonary vascular tone ongas exchangeincanine oleic acid pulmonary edema. J Appl Physiol 65(2):662-668, 1988.
27. Sigurdsson GH, Vallgren S, Christenson JT: Influence of aspirin and steroids on acute lung injury after i.v. Injection of a sclerosing agent. Acta Chir Scand 155(3):163-170, 1989.
28. Chelucci GL, Boncinelli S, Marsili M, Lorenzi P, Allegra A, Linden M, Chelucci A, Merciai V, Cresci F, Rostagno C: Aspirin effect on early and late changes in acute lung injury in sheep. Intensive Care Med 19(1):13-21, 1993.
29. Goncalves de Moraes VL, Boris Vargaftig B, Lefort J, Meager A, Chignard M: Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung. Br J Pharmacol 117(8):1792-1796, 1996.
30. Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD: Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 174(8):5033-5039, 2005.
31. Zarbock A, Singbartl K, Ley K: Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116(12):3211-3219, 2006.
32. Jin S-W, Zhang L, Lian Q-Q, Liu D, Wu P, Yao S-L, Ye D-Y: Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth Analg 104(2):369-377, 2007.
33. El Kebir D, József L, Pan W, Wang L, Petasis Na, Serhan CN, Filep JG: 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 180(4):311-319, 2009.
34. Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, Croze RH, Carlo T, Pfeffer Ma, Levy BD: Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 6(2):256-266, 2013.
35. Tuinman PR, Müller MC, Jongsma G, Hegeman Ma, Juffermans NP: High-dose acetylsalicylic acid is superior to low-dose as well as to clopidogrel in preventing lipopolysaccharide-induced lung injury in mice. Shock 40(4):334-338, 2013.
36. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA: Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 119(11):3450-3461, 2009.
37. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, Toy P, Werb Z, Looney MR: Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 122(7):2661-2671, 2012.
38. Ortiz-Muñoz G, Mallavia B, Bins A, Headley M, Krummel MF, Looney MR: Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. Blood 124(17):2625-2634, 2014.
39. Tang H, Liu Y, Yan C, Petasis NA, Serhan CN, Gao H: Protective actions of aspirin-triggered (17R) resolvin D1 and its analogue, 17R-hydroxy-19-para-fluorophenoxy-resolvin D1 methyl ester, in C5a-dependent IgG immune com-plex-induced inflammation and lung injury. J Immunol 193(7):3769-3778, 2014.
40. Cox R, Phillips O, Fukumoto J, Fukumoto I, Parthasarathy PT, Arias S, Cho Y, Lockey RF, Kolliputi N: Enhanced resolution of hyperoxic acute lung injury as a result of aspirin triggered resolvin D1 treatment. Am J Respir Cell Mol Biol 53(3):422-435, 2015.
41. Leeman M, Delcroix M, Vachiéry JL, Mélot C, Naeije R: Blunted hypoxic vasoconstriction in oleic acid lung injury: effect of cyclooxygenase inhibitors. J Appl Physiol 72(1):251-258, 1992.
42. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell Ra, Choi a M: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6(4):422-428, 2000.
43. Otterbein LE, Soares MP, Yamashita K, Bach FH: Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24(8):449-455, 2003.
44. O'Neal HR, Koyama T, Koehler EAS, Siew E, Curtis BR, Fremont RD, May AK, Bernard GR, Ware LB: Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 39(6):1343-1350, 2011.
45. Chen W, Janz DR, Bastarache JA, May AK, O'Neal HR, Bernard GR, Ware LB: Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients. Crit Care Med 43:801-807, 2015.
46. Boyle AJ, Di Gangi S, Hamid UI, Mottram L-J, McNamee L, White G, Cross LJM, McNamee JJ, O'Kane CM, McAuley DF: Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care 19(1):109, 2015.
47. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ: Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 139(2):289-295, 2011.
48. Kor DJ, Erlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, Talmor DS: Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients∗. Crit Care Med 39(11):2393-2400, 2011.
49. Harr JN, Moore EE, Johnson J, Chin TL, Wohlauer MV, Maier R, Cuschieri J, Sperry J, Banerjee A, Silliman CC, et al.: Antiplatelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients∗. Crit Care Med 41(2):399-404, 2013.
50. Tuinman PR, Vlaar AP, Binnenkade JM, Juffermans NP: The effect of aspirin in transfusion-related acute lung injury in critically ill patients. Anaesthesia 67(6):594-599, 2012.
51. Mazzeffi M, Kassa W, Gammie J, Tanaka K, Roman P, Zhan M, Griffith B, Rock P: Preoperative aspirin use and lung injury after aortic valve replacement surgery: a retrospective cohort study. Anesth Analg 121(2):271-277, 2015.
52. Vincent JL, Brimioulle S, Berre J, Kahn RJ: Prevention of the adult respiratory distress syndrome with dipyridamole. Crit Care Med 13(10):783-785, 1985.
53. Grant RL: Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ 348:f7450, 2014.
54. Sossdorf M, Otto GP, Boettel J, Winning J, Losche W: Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care 17(1):402, 2013.
55. Winning J, Neumann J, Kohl M, Claus Ra, Reinhart K, Bauer M, Losche W: Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 38(1):32-37, 2010.
56. Lösche W, Boettel J, Kabisch B, Winning J, Claus Ra, Bauer M: Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients? Thrombosis 2012:1-8, 2012.
57. Marik PE: Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 344(9):665-671, 2001.
58. Clària J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosa-noids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92(21):9475-9479, 1995.
59. Chiang N, Arita M, Serhan CN: Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 73(3-4):163-177, 2005.
60. Serhan CN: Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1212(1):1-25, 1994.
61. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 303(5663):1532-1535, 2004.
62. Grommes J, Alard JE, Drechsler M, Wantha S, Mörgelin M, Kuebler WM, Jacobs M, Von Hundelshausen P, Markart P, Wygrecka M, et al.: Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med 185(6):628-636, 2012.
63. Tuinman PR, Müller MC, Jongsma G, Hegeman M, Juffermans NP: High-dose acetylsalicylic acid is superior to low-dose as well as to clopidogrel in preventing lipopolysaccharide-induced lung injury in mice. Shock 40(4):334-338, 2013.
64. Schrör K: Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23(4):349-356, 1997.
65. Cornet AD, Oudemans-van Straaten HM, Schultz MJ, Juffermans NP, Tuinman PR: Anticoagulantsfor ARDS: facts andfuture. Neth J Crit Care 18(6):3-8, 2014.
66. Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS: Acute respiratory distress syndrome: the Berlin Definition. JAMA 307(23):2526-2533, 2012.
67. McAuley D. The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury (ARENA) (NCT01659307) [Internet]. Clin Regist [cited Oct 1, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT01659307. Accessed September 10, 2015.
68. McAuley D. ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial (NCT02326350) [Internet]. Clin Regist [cited Oct 1, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT01659307. Accessed September 10, 2015.
69. Kor DJ, Talmor DS, Banner-Goodspeed VM, Carter RE, Hinds R, Park PK, Gajic O, Gong MN: Lung injury prevention with aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open 2(5):e001606-e11606, 2012.